Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Unfortunately... I don't think it will be running

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biopharm Member Profile
Member Level 
Followed By 82
Posts 13,194
Boards Moderated 1
Alias Born 10/12/10
160x600 placeholder
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
Sanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche Dow Jones News - 7/23/2019 1:47:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint Dow Jones News - 6/20/2019 7:37:00 PM
Genentech Gets FDA Priority Review For Rituxan in Children With Rare Blood Vessel Disorders Dow Jones News - 6/12/2019 6:48:00 AM
Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study Dow Jones News - 6/11/2019 7:25:00 AM
Roche Says Peter Voser to Step Down as Director; Makes Changes to Executive Committee Dow Jones News - 6/11/2019 1:51:00 AM
Roche's Genentech Gets FDA Priority Approval For Polivy Regimen Dow Jones News - 6/10/2019 12:58:00 PM
Correction to Roche, Spark Therapeutics Article Dow Jones News - 6/10/2019 2:12:00 AM
biopharm Member Level  Friday, 05/17/13 03:28:36 PM
Re: Willsmith3 post# 89
Post # of 138 
Unfortunately... I don't think it will be running far. A new cancer drug will be needed.... and not PD-L1.

PD-1 (Bristol Myers Squibb) or PD-L1... are no comparison to Bavituximab, Peregrine Pharmaceuticals lead drug candidate. I'd like to hear ones reasoning though... always good to know the competition

GoodJohnHunting over on the Peregrine Board ... and others have discussed this and at ACSO... this is a little glimpse that will be coming on why Bavituximab is better than PD-1 ... or PD-L1.

I've discussed in the past something called "notch signalling", and its critical role in determination of M1 versus M2 polarization. The beauty of Bavituximab, is its influence or activation within the microenvironment that govern the processes of M1, M2 polarization. What's even more mind boggling is that there is clear evidence of active polarization from M2 to M1 state via the increased presence of IL12 (tumoricidal effect), with Bavituximab administration. As you may recall, this was mentioned as a signaling chemical, and, as I summized along with Nitric Oxide.

I will say this, when someone discovers the mechanisms governing macrophage polarization, and harness what Bavituximab claims to do, they will undoubtedly be adorned with Nobel's Prize in Medicine.

Now tell me how PD-1, PD-L1 compares to Bavituximab? There is no comparison, in my opinion.

Thanks to GJH for this explanation... more and more people can understand the differences between PD-1, PD-L1... vs Bavituximab.

Its more like the debate on who can invent the better wheel.... the problem is Peregrine has the IP and global rights on the wheel itself ... the rest are those simply trying to recreate it and a bumpy road it will be.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist